{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005576173,0.0002565929,0.0006612406,0.0005271815,0.00006859771,0.00005446629,0.0001443086,0.0002406728,0.0001743209],"category_scores_gemma":[0.00005644666,0.0002015466,0.00001319528,0.0006173435,0.0001631349,0.0005795851,0.00005225877,0.000600329,0.00001148036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008688731,"about_ca_system_score_gemma":0.0008163056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002043127,"about_ca_topic_score_gemma":0.0005107737,"domain_scores_codex":[0.9978244,0.0002975633,0.0005493316,0.0006087988,0.0003353266,0.0003845443],"domain_scores_gemma":[0.999105,0.0001414644,0.0001762677,0.0002794457,0.0001209927,0.0001767838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7615173,0.0410376,0.03966582,0.0003788258,0.0002897566,0.001781845,0.01003888,0.00006630912,0.03827224,0.001055211,0.002696331,0.1031998],"study_design_scores_gemma":[0.7865131,0.1359274,0.06188533,0.001371819,0.0001101367,0.00005252402,0.0004562224,0.001760978,0.002260846,0.0004626954,0.00861908,0.0005798321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953721,0.0003081219,0.0000453358,0.0005598791,0.0003601155,0.002388487,0.00002284123,0.00009839472,0.0008447329],"genre_scores_gemma":[0.9974567,0.00004865121,0.0009209593,0.0005876909,0.0001168783,0.0002942797,0.0004119539,0.00005870688,0.0001042109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.10262,"threshold_uncertainty_score":0.8218831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04736721586451495,"score_gpt":0.3932493215087382,"score_spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}